Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Trellus Health PLC ( (GB:TRLS) ) has shared an announcement.
Trellus Health has converted approximately £65,000 of principal and accrued interest from its secured convertible loan notes into 16,804,593 new ordinary shares, completing the conversion of its first tranche notes. The new shares are expected to begin trading on AIM around 25 February 2026, increasing the company’s issued share capital to 208,719,361 ordinary shares and setting a new base for shareholders’ voting-rights calculations under UK disclosure rules.
The enlarged share capital following admission clarifies the company’s capital structure and may modestly reduce its debt burden by eliminating the converted notes. The updated total voting rights figure will be used by investors to assess whether they must disclose holdings or changes in their interests, improving transparency around significant shareholdings in Trellus Health.
The most recent analyst rating on (GB:TRLS) stock is a Hold with a £0.74 price target. To see the full list of analyst forecasts on Trellus Health PLC stock, see the GB:TRLS Stock Forecast page.
Spark’s Take on GB:TRLS Stock
According to Spark, TipRanks’ AI Analyst, GB:TRLS is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, negative free cash flow, and declining equity—despite the benefit of having no debt. Technicals are the main positive, with strong momentum above major moving averages, but valuation remains constrained by loss-making results and no indicated dividend yield.
To see Spark’s full report on GB:TRLS stock, click here.
More about Trellus Health PLC
Trellus Health plc is a healthcare company that delivers Trellus Elevate, a digital, value-based condition management platform that integrates data analytics with personalised, resilience-based programmes for complex chronic diseases. The group initially focuses on high-cost gastrointestinal conditions such as inflammatory bowel disease, and also partners with pharmaceutical companies to support clinical trials and commercialisation through patient engagement and adherence solutions.
Average Trading Volume: 5,001,190
Technical Sentiment Signal: Hold
Current Market Cap: £1.77M
See more data about TRLS stock on TipRanks’ Stock Analysis page.